Company news

Apogee Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 27, 2024

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 22, 2024

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 14, 2024

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 12, 2024

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

May 5, 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

March 24, 2024

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

March 11, 2024

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

March 6, 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

March 4, 2024

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead o...

March 4, 2024

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

March 3, 2024

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

November 12, 2023

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

September 26, 2023

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

September 13, 2023

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

August 27, 2023

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

August 20, 2023

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

August 6, 2023

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

August 1, 2023

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

July 17, 2023

← Newer news releases

Calls

Decks

The 5 newest of 11 decks. Every deck is listed under its year.